SOURCE: Motus GI Holdings, Inc.

Motus GI Holdings, Inc.

April 27, 2017 07:30 ET

Motus GI Holdings, Inc. Announces First U.S. Ambulatory Endoscopy Center Clinical Procedures Using the Pure-Vu™ System

NEW HOPE, PA--(Marketwired - April 27, 2017) - Motus GI Holdings, Inc., ("Motus GI" or the "Company"), a medical device company dedicated to improving colonoscopy outcomes and experiences, today announced that it has completed its first series of clinical procedures using the Pure-Vu™ system in a U.S. ambulatory endoscopy center ("AEC") by Gerald Bertiger, MD, Gastroenterologist, at Hillmont GI, in Flourtown, PA. Dr. Bertiger's first clinical use was on March 27th, 2017 in a patient who previously failed multiple colonoscopies due to an inadequate prep, however, with the use of the Pure-Vu system was able to perform a successful colonoscopy. Dr. Bertiger and his colleagues have since performed additional colonoscopy procedures using Pure-Vu system.

Dr. Bertiger commented, "The Pure-Vu system was easy to use and worked effectively in cleansing my patient's colon to successfully complete the colonoscopy procedure. I believe the Pure-Vu system is a simple, safe and effective solution for cleaning inadequately prepared colons in patients who have had previous failed preps or may be unable to tolerate or consume their entire prep. The Pure-Vu system allowed me to provide a thorough exam and avoid rescheduling and eliminate the need for procedures having to be repeated earlier than the medical guidelines advise, which unfortunately is often the case with patients that are poorly prepped."

The Pure-Vu system uses a mixture of water and air to loosen debris from the colon mucosa while simultaneously evacuating the bowel contents, clearing the way for the endoscopist to perform a high-quality examination -- even when the patient did not complete a successful prep on his or her own. The Pure-Vu system consists of a disposable component and a workstation controller. The disposable fits over standard colonoscopes without interfering with the working channel, allowing the physician to intra-procedurally clean and then visualize, diagnose and, if necessary, treat the colon in a standard fashion.

"We are excited to have Dr. Bertiger use the Pure-Vu system, validate previously reported European data and demonstrate the benefit the Pure-Vu system can bring to patients," said Mark Pomeranz, CEO of Motus GI. "This is a significant milestone for the company as we initiate the pilot commercial introduction of the Pure-Vu system in the U.S., with our goal to provide physicians with more flexibility in treating their patients while addressing issues such as early repeat procedures, missed adenomas, reduced patient satisfaction and higher costs that are associated with poorly prepared colons."

Motus GI received 510(k) clearance from the U.S. Food and Drug Administration ("FDA") to market its Pure-Vu system in 2016, and it is currently being introduced on a pilot basis. The Company expects to move to a full commercial launch in the U.S. and international markets in the second half of 2018.

About Colorectal Cancer
Colorectal cancer ("CRC") is the second leading cause of cancer-related deaths in the U.S. with approximately 50,000 deaths and 140,000 new cases of CRC diagnosed each year. The lifetime risk of developing CRC is about 1 in 20 -- or 5%. Through the use of colonoscopies, however, CRC has become one of the most preventable cancers.

About Colonoscopy
Colonoscopy is one of the most common medical procedures with an estimated 15 million procedures performed in the U.S. annually. Approximately 60% percent of colonoscopies are conducted as the standard of care for detecting CRC, while the remaining 40% are focused on diagnosis and surveillance of patients with gastrointestinal issues such as bleeding, inflammatory bowel disease and motility challenges.

About Motus GI
Motus GI Holdings, Inc. is a medical technology company with subsidiaries in the U.S. and Israel. The Company was spun out of the NGT incubator located in Israel in 2011 by Orchestra Medical Ventures. The Company is focused on the development and commercialization of the Pure-Vu™ system to improve the colonoscopy experience for physicians, patients and payers by enhancing the quality and cost-effectiveness of the exam. The Pure-Vu™ system is indicated to integrate with standard colonoscopes to perform intra-procedural cleaning of a poorly prepared colon, thereby reducing the sole dependency on a successful pre-procedural prep regimen to gain clear visualization of the colon mucosa. For more information, visit

Forward-Looking Statements
This press release contains certain forward-looking statements, including those relating to the Company's product development, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. The Company has made every reasonable effort to ensure the information and assumptions on which these statements are based are current, reasonable and complete. However, a variety of factors, many of which are beyond the Company's control, affect the Company's operations, performance, business strategy and results and there can be no assurances that the Company's actual results will not differ materially from those indicated herein. Additional written and oral forward-looking statements may be made by the Company from time to time. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact Information